# Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

> **NCT06295549** · PHASE1 · TERMINATED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 11 (actual)

## Conditions studied

- Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** LUCAR-G39P cells product

## Key facts

- **NCT ID:** NCT06295549
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-11
- **Primary completion:** 2025-06-11
- **Final completion:** 2025-08-22
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Achieve the proof of concept.
- **Last updated:** 2025-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06295549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06295549, "Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT06295549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*